基本信息
浏览量:567
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. His leadership in targeted therapeutics resulted in being selected for ASCO’s plenary presentation in 2020 and 2023 and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine.
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. His leadership in targeted therapeutics resulted in being selected for ASCO’s plenary presentation in 2020 and 2023 and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine.
研究兴趣
论文共 777 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Targeted Oncologyno. 2 (2024): 1-4
Douglas I. Lin,Richard S. P. Huang,Ioannis Ladas,Rachel B. Keller,Nimesh R. Patel, Sotirios Lakis,Brennan Decker,Tyler Janovitz,Douglas A. Mata, Jeffrey S. Ross,Jo-Anne Vergilio,Julia A. Elvin,
FRONTIERS IN ONCOLOGY (2024): 1328512-1328512
Joel W Neal,Katherine Minichiello, Ryan Brennick,Richard S P Huang,Matthew C Hiemenz, Cornel Amler,Jyoti Patel,Roy Herbst,Karen L Reckamp,Hossein Borghaei,Louise Highleyman,Mary W Redman,
Matthew Liu,Ioannis Vathiotis,Charles J. Robbins, Nay Nwe Nyein Chan,Myrto Moutafi,Sneha Burela,Vasiliki Xirou,Kurt A. Schalper,Roy S. Herbst,Konstantinos Syrigos,David L. Rimm
Modern Pathologypp.100556-100556, (2024)
H. Borghaei,F. de Marinis, D. Dumoulin, C. Reynolds, W. S. M. E. Theelen,I. Percent,V. Gutierrez Calderon,M. L. Johnson, A. Madroszyk-Flandin, E. B. Garon, K. He, D. Planchard,
ANNALS OF ONCOLOGYno. 1 (2024): 66-76
Daniel R. Carrizosa,Jieling Miao,Karen L. Reckamp,Konstantin H. Dragnev,Paul Joseph Hesketh,Wade Thomas Iams,Brian S. Henick, Cheryl M. Czerlanis, Frank DeSanto, Jamie Sundstrom, Judy Johnson, Lucy Gansauer,
Journal of Clinical Oncologyno. 16_suppl (2024): 11019-11019
Journal of Clinical Oncologyno. 16_suppl (2024)
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 1 (2024): 29-32
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn